The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community

Affiliations

Comment

Takashi Komori. Neuro Oncol. 2019.

. 2019 Dec 17;21(12):1485-1486.

doi: 10.1093/neuonc/noz186.

¹ Department of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.

No abstract available

Comment on

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network. Appay R, et al. Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124. Neuro Oncol. 2019. PMID: 31832685 Free PMC article.

1. Louis DN, Perry A, Reifenberger G, et al. . The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. - PubMed
1. Olar A, Wani KM, Alfaro-Munoz KD, et al. . IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015;129(4):585–596. - PMC - PubMed
1. Reuss DE, Mamatjan Y, Schrimpf D, et al. . IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathol. 2015;129(6):867–873. - PMC - PubMed
1. Aoki K, Nakamura H, Suzuki H, et al. . Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018; 20:66–77. - PMC - PubMed
1. Brat DJ, Verhaak RG, Aldape KD, et al. ; The Cancer Genome Atlas Research Network Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–2498. - PMC - PubMed